Is BMS/AstraZeneca's Dapagliflozin More Than Just Another Oral Diabetes Drug?
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.
Phase III results with metformin leave some disappointed, while another study hints of niche role in insulin-resistant patients.